Last reviewed · How we verify
Extra-fine hydrofluoroalkane-beclomethasone dipropionate
Glucocorticoid receptor agonist
Glucocorticoid receptor agonist Used for Asthma.
At a glance
| Generic name | Extra-fine hydrofluoroalkane-beclomethasone dipropionate |
|---|---|
| Also known as | Qvar®, Qvar |
| Sponsor | Research in Real-Life Ltd |
| Drug class | Glucocorticoid |
| Target | Glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Respiratory |
| Phase | Phase 2 |
Mechanism of action
Beclomethasone dipropionate acts as a potent glucocorticoid receptor agonist, leading to anti-inflammatory and immunosuppressive effects.
Approved indications
- Asthma
Common side effects
- Oral thrush
- Hypersensitivity reactions
Key clinical trials
- Does Extra-fine Hydrofluoroalkane-beclomethasone Dipropionate (HFA-BDP) Suppress Small Airways Inflammation in Chronic Obstructive Pulmonary Disease (COPD)? (PHASE4)
- Real-world Effectiveness and Cost-effectiveness of Qvar Versus FP, a US Study
- Qvar vs FP in Pediatrics
- Real-world Effectiveness and Cost-effectiveness of Leading Inhaled Corticosteroids in Asthma Management
- Qvar Therapy in Smoking Asthmatics
- Qvar Versus Clenil, a General Practice Research Database Study
- Real-world Effectiveness and Cost-effectiveness of HFA-beclometasone Compared With ICS/LABA Combination Therapy
- Real-life Effectiveness and Cost-effectiveness of Qvar Versus FP and BDP in the Management of COPD
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: